International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
To investigate the feasibility of our novel image-based high-dose-rate interstitial brachytherapy (HDR-ISBT) for uterine cervical cancer, we evaluated the dose-volume histogram (DVH) according to the recommendations of the Gynecological GEC-ESTRO Working Group for image-based intracavitary brachytherapy (ICBT). ⋯ Although the targets were advanced and difficult to treat effectively by ICBT, MRI-aided image-based ISBT showed favorable results for CTV and organs at risk compared with previously reported image-based ICBT results.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
To determine the short- and medium-term effects of a single high-dose-rate brachytherapy fraction of 15 Gy and hypofractionated external beam radiation therapy for prostate cancer. ⋯ Treatment is well tolerated in the short and medium term, with low toxicity and encouraging early indicators of disease control.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. ⋯ Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Hypofractionated radiotherapy for favorable risk prostate cancer.
Since the recognition that prostate cancer probably has a low alpha/beta ratio, hypofractionated radiotherapy has become an attractive treatment option for localized prostate cancer. However, there is little experience with the use of hypofractionation delivering a high biologically equivalent dose. We report our experience with high-dose hypofractionated radiotherapy. ⋯ This hypofractionated regimen provides excellent biochemical control in favorable risk prostate cancer with an acceptable rate of late toxicity. Further studies exploring this hypofractionation regimen are warranted.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
RapidArc radiation therapy: first year experience at the University of Alabama at Birmingham.
To evaluate treatment planning and delivery for patients treated during our initial year of experience with RapidArc radiation therapy. ⋯ RapidArc plans have quality comparable to our standard SG-DMLC IMRT technique, and are delivered with similar accuracy in shorter time.